Global UAV Technologies (YRLLF) announced the closing of a non-brokered private placement raising gross proceeds of $4,445,000. The offering comprised 11,112,500 common shares at $0.40 each. The company paid $38,240.00 in cash finders' fees and issued 95,600 broker warrants, exercisable for one share each at $0.40 until October 15, 2028.
Despite the announced closing, the offering remains subject to necessary regulatory approvals, including Canadian Securities Exchange approval. Trading remains halted pending completion of the exchange's review of a proposed transaction. The company intends to use net proceeds partly for intellectual property development and assessment.
Global UAV Technologies (YRLLF) plans a share consolidation at a ratio of 1.324206 existing shares for one share, effective October 13, 2026.
Issued and outstanding shares will move from 43,698,801 to 33,000,002, subject to rounding adjustments. Fractional shares will be rounded up. The consolidation is intended to satisfy a requirement for no more than 33,000,000 shares immediately before closing the proposed business combination with Nexus Peptide Sciences, under an existing amalgamation agreement.
The transaction remains subject to Canadian Securities Exchange approval and other closing conditions. Trading remains halted pending completion of the exchange's review. Outstanding convertible securities' exercise or conversion prices and issuable share counts will be proportionately adjusted.
Global UAV Technologies (CSE: UAV, OTC: YRLLF) has entered into a definitive amalgamation agreement with Nexus Peptide Sciences and Newco for a three‑cornered amalgamation that will make Nexus a wholly owned subsidiary (Amalco) of Global UAV.
On closing, Nexus shareholders will receive an aggregate 20,500,000 Global UAV shares and 7,000,000 warrants, each warrant exercisable at $0.10 for two years. Global UAV expects to have no more than 33,000,000 shares outstanding immediately before closing and about 54,500,000 shares after the transaction, excluding a planned equity financing of $3–5 million at $0.40 per share. The deal is classified as a Fundamental Change by the CSE and is subject to due diligence, audited Nexus financials, regulatory and CSE acceptance, with a completion deadline of September 30, 2026. Trading in Global UAV shares remains halted, and completion is not assured.
Global UAV Technologies (CSE: UAV, OTC: YRLLF) has signed a non-binding letter of intent dated July 27, 2026 to acquire all outstanding securities of Nexus Peptide Sciences, a private Vancouver-based peptide biotechnology company. The transaction would be a Fundamental Change under Canadian Securities Exchange policies and is an arm’s length deal.
On closing, Global UAV would issue 20,300,000 shares and 7,000,000 warrants to Nexus shareholders, with each warrant exercisable at $0.10 for two years. Immediately before closing, Global UAV plans to have no more than 33,000,000 shares and 17,000,000 warrants outstanding. The company also anticipates a finder’s fee of $100,000 cash and 1,000,000 shares, and intends to complete an equity financing of $3–5 million by closing. Nexus would become a wholly owned subsidiary, and the resulting issuer’s five-member board would include three Nexus nominees and two current Global UAV directors. Completion remains subject to due diligence, definitive agreement, audited financials, CSE acceptance and other customary conditions, with an LOI deadline of August 31, 2026 and no assurance of closing.